All In Biotech

Drug Trial Radar · NCT06684743

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 690,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

690,000

Planned (sponsor's estimate)

Start

Nov 18, 2024

Primary completion

May 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Tor Biering-SørensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.

Conditions

  • RSV

Interventions

  • RSV prefusion F protein-based vaccineBiological

    For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospitalization for RSV-related respiratory tract diseaseTime frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte

    Copenhagen, Denmark

  • Danske Lægers Vaccinations Service

    Søborg, Denmark

  • General Public Health Directorate of Galician Health Service

    Santiago de Compostela, A Coruña, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.